blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3315128

EP3315128 - DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION [Right-click to bookmark this link]
Former [2018/18]DOSING REGIMEN OF THERAPEUTIC AGENT FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION
[2020/50]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 07.04.2026
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  01.12.2020
FormerExamination is in progress
Status updated on  17.02.2020
FormerRequest for examination was made
Status updated on  30.03.2018
FormerThe international publication has been made
Status updated on  30.12.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Shionogi & Co., Ltd.
1-8, Doshomachi 3-chome
Chuo-ku
Osaka 541-0045 / JP
[2021/20]
Former [2018/18]For all designated states
Kissei Pharmaceutical Co., Ltd.
19-48, Yoshino
Matsumoto-shi, Nagano 399-8710 / JP
Inventor(s)01 / SHIMIZU, Yoshitaka
c/o Tokyo Head Office
Kissei Pharmaceutical Co. Ltd.
3-1-3 Koishikawa
Bunkyo-ku
Tokyo 112-0002 / JP
02 / YAMANO, Hitoshi
c/o Tokyo Head Office
Kissei Pharmaceutical Co. Ltd.
3-1-3 Koishikawa
Bunkyo-ku
Tokyo 112-0002 / JP
03 / KIYONO, Yuji
c/o Tokyo Head Office
Kissei Pharmaceutical Co. Ltd.
3-1-3 Koishikawa
Bunkyo-ku
Tokyo 112-0002 / JP
04 / IJIRO, Tomoyuki
c/o Central Research Laboratories
Kissei Pharmaceutical Co. Ltd.
4365-1 Hotaka-Kashiwabara
Azumino-shi Nagano 399-8304 / JP
 [2018/18]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2018/18]
Application number, filing date15896367.826.06.2015
[2018/18]
WO2015JP68438
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016208045
Date:29.12.2016
Language:JA
[2016/52]
Type: A1 Application with search report 
No.:EP3315128
Date:02.05.2018
Language:EN
[2018/18]
Type: B1 Patent specification 
No.:EP3315128
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)International search report - published on:JP29.12.2016
(Supplementary) European search report - dispatched on:EP17.01.2019
ClassificationIPC:A61K31/427, A61P25/00
[2018/18]
CPC:
A61K31/427 (EP,US); A61P25/14 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:DOSIERSCHEMA FÜR ROVATIRELIN FÜR MIT ATAXIE EINHERGEHENDE SPINOZEREBELLÄRE DEGENERATION[2020/50]
English:DOSING REGIMEN OF ROVATIRELIN FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION[2020/50]
French:RÉGIME DE DOSAGE DU ROVATIRELIN CONTRE L'ATAXIE ASSOCIÉE À LA DÉGÉNÉRESCENCE SPINO-CÉRÉBELLEUSE[2020/50]
Former [2018/18]DOSIERSCHEMA FÜR EIN THERAPEUTIKUM FÜR MIT ATAXIE EINHERGEHENDE SPINOZEREBELLÄRE DEGENERATION
Former [2018/18]DOSING REGIMEN OF THERAPEUTIC AGENT FOR ATAXIA ASSOCIATED WITH SPINOCEREBELLAR DEGENERATION
Former [2018/18]RÉGIME DE DOSAGE D'AGENT THÉRAPEUTIQUE CONTRE L'ATAXIE ASSOCIÉE À LA DÉGÉNÉRESCENCE SPINO-CÉRÉBELLEUSE
Entry into regional phase10.01.2018Translation filed 
10.01.2018National basic fee paid 
10.01.2018Search fee paid 
10.01.2018Designation fee(s) paid 
10.01.2018Examination fee paid 
Examination procedure10.01.2018Examination requested  [2018/18]
10.01.2018Date on which the examining division has become responsible
09.08.2019Amendment by applicant (claims and/or description)
20.02.2020Despatch of a communication from the examining division (Time limit: M04)
23.03.2020Reply to a communication from the examining division
02.12.2020Communication of intention to grant the patent
12.04.2021Fee for grant paid
12.04.2021Fee for publishing/printing paid
12.04.2021Receipt of the translation of the claim(s)
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
18.01.2018Renewal fee patent year 03
25.06.2018Renewal fee patent year 04
17.06.2019Renewal fee patent year 05
31.03.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.06.2015
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
MT19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
[2024/42]
Former [2024/22]HU26.06.2015
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2023/33]HU26.06.2015
AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2023/30]AL19.05.2021
AT19.05.2021
CY19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/29]AL19.05.2021
AT19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SI19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/26]AL19.05.2021
AT19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/23]AT19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/18]AT19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
LU26.06.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/10]AT19.05.2021
CZ19.05.2021
EE19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
IS22.12.2021
Former [2022/09]AT19.05.2021
CZ19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SK19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2022/07]AT19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/51]AT19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
PT20.09.2021
Former [2021/50]AT19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
PT20.09.2021
Former [2021/49]AT19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]AT19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]AT19.05.2021
LT19.05.2021
Documents cited:Search[I] WO2006028277  (SHIONOGI & CO et al.) [I] 1-7 * page 8, line 9 - line 10 * * page 9, line 31 - line 32 * * page 10, line 28 - page 12, line 20 * * page 13, line 15 - line 25 * * page 13, line 30 - line 37 * * page 14, line 8 - line 15 * * claims 1,5,10 *
 [I]   FROESTL WOLFGANG ET AL: "Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs", JOURNAL OF ALZHEIMER'S DISEASE, IOS PRESS, NL, vol. 34, no. 1, 1 January 2013 (2013-01-01), pages 1 - 114, XP009186604, ISSN: 1387-2877, DOI: 10.3233/JAD-121729 [I] 1-7 * page 6, column l, paragraph 5 *

DOI:   http://dx.doi.org/10.3233/JAD-121729
International search[Y] JP2008512344   [Y] 1-7 * , claims; paragraphs [0017] to [0021]; example 1; test example 1 & US 2008/0027116 A1 & WO 2006/028277 A1 & EP 1786423 A1 & CA 2579720 A *
 [Y]   HAJIME KAINUMA ET AL.: "Clinical Phase I Study of TA-0910. Oral Repeated Dose Study.", JOURNAL OF CLINICAL THERAPEUTICS & MEDICINES, vol. 13, no. 10, June 1997 (1997-06-01), pages 2517 - 2532, XP009504662 [Y] 1-7 * , Introduction, page 2519, right column, 7th line from the bottom to page 2520, left column, line 5, page 2521, left column, lines 12 to 20, page 2524, left column, 4th line from the bottom to right column, line 10, page 2530, left column, lines 7 to 14, fig. 1, 3 to 6 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.